Condition: HIV I Infection · Sponsor: University of Melbourne
The purpose of this study is to evaluate whether a single dose of Nivolumab in people living with HIV can reduce the latent reservoir. The latent HIV reservoir is a group of immune system cells in the body that are infected with HIV but are not actively producing new virus. This is the reason why people living with HIV are unable to stop their antiretroviral treatment.
This description comes directly from the study's public registry record.
Jennifer Audsley, BAppSC(Hons), PhD · +61 (0)3 8344 3266 · jennifer.audsley@unimelb.edu.au
Always discuss trial participation with your own doctor first.
| Alfred Hospital - Department of Infecious Diseases | Melbourne, Victoria, Australia | Recruiting |
| Tan Tock Seng Hospital | Singapore, Singapore | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05187429